公开(公告)号：US20240166606A1

公开(公告)日：2024-05-23

申请号：US18421419

申请日：2024-01-24

Applicant: Shanghai AB PharmaTech Ltd.

Inventor： Zheng-Yun James ZHAN

IPC: C07D215/233 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K45/06 ,  A61P11/00 ,  A61P35/00 ,  A61P35/02 ,  C07D215/48 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12

CPC classification number: C07D215/233 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K45/06 ,  A61P11/00 ,  A61P35/00 ,  A61P35/02 ,  C07D215/48 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07B2200/05

Abstract: Disclosed are compounds of Formula IIIb, their stereoisomers, tautomers, deuterates, pharmacologically acceptable salts, or hydrates thereof, methods of their preparation and pharmaceutical compositions and uses comprising such compounds. The Formula IIIb compounds are useful and highly effective as multi-targeted tyrosine kinase inhibitors in treating several kinds of cancers such as pancreatic cancer, lung cancer, renal cancer, liver cancer, gastric cancer, cervical cancer, leukemia, prostatic cancer, and other antitumor uses.

公开(公告)号：US20240383858A1

公开(公告)日：2024-11-21

申请号：US18786042

申请日：2024-07-26

Applicant: Shanghai AB PharmaTech Ltd.

Inventor： Zheng-Yun James ZHAN

IPC: C07D215/233 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K45/06 ,  A61P11/00 ,  A61P35/00 ,  A61P35/02 ,  C07D215/48 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12

Abstract: Disclosed are compounds of Formula III, their stereoisomers, tautomers, deuterates, pharmacologically acceptable salts, or hydrates thereof, methods of their preparation and pharmaceutical compositions comprising such compounds. The Formula III compounds are useful and highly effective as multi-targeted tyrosine kinase inhibitors in treating several kinds of cancers such as liver cancer, bladder cancer, thyroid cancer, cervical cancer, leukemia.

公开(公告)号：US20230124784A1

公开(公告)日：2023-04-20

申请号：US17886930

申请日：2022-08-12

Applicant: Shanghai AB PharmaTech Ltd.

Inventor： Zheng-Yun James ZHAN

IPC: A61K31/47 ,  C07D215/48 ,  C07D401/06 ,  C07D405/12 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/506 ,  A61P35/00 ,  A61P11/00 ,  A61P35/02 ,  A61K31/44

Abstract: Disclosed are compounds of Formula IIIb, their stereoisomers, tautomers, deuterates, pharmacologically acceptable salts, or hydrates thereof, methods of their preparation and pharmaceutical compositions and uses comprising such compounds. The Formula IIIb compounds are useful and highly effective as multi-targeted tyrosine kinase inhibitors in treating several kinds of cancers such as pancreatic cancer, lung cancer, renal cancer, liver cancer, gastric cancer, cervical cancer, leukemia, prostatic cancer, and other antitumor uses.

公开(公告)号：US20230123696A1

公开(公告)日：2023-04-20

申请号：US17819157

申请日：2022-08-11

Applicant: Shanghai AB PharmaTech Ltd.

Inventor： Zheng-Yun James ZHAN

IPC: C07D215/233 ,  A61K45/06 ,  C07D405/12 ,  C07D401/12

Abstract: Disclosed are compounds of Formula III, their stereoisomers, tautomers, deuterates, pharmacologically acceptable salts, or hydrates thereof, methods of their preparation and pharmaceutical compositions comprising such compounds. The Formula III compounds are useful and highly effective as multi-targeted tyrosine kinase inhibitors in treating several kinds of cancers such as liver cancer, bladder cancer, thyroid cancer, cervical cancer, leukemia.